指南与共识重症综合管理与镇静镇痛

美国胸科医师学会临床实践指南:危重症成人新鲜冰冻血浆与血小板输注

Transfusion of Fresh Frozen Plasma and Platelets in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline.
指南 / 共识 · Chest · 2025-03-10
一句话结论美国胸科医师学会指南:危重症血小板减少或凝血功能障碍者输注血小板或新鲜冰冻血浆前应行风险/获益评估,多数患者避免输注获益。

该指南由美国胸科医师学会制定,针对危重症成人血小板减少(伴或不伴活动性出血)及常见操作预防性输注血小板和新鲜冰冻血浆的问题,提出7个PICO问题并系统综述证据。初检7,172项研究,筛选后100篇全文复习,最终16项研究纳入(1项随机对照试验和15项观察性研究),所有问题的证据确定性均为极低。专家组采用GRADE方法并修改德尔菲技术达成共识,形成7条条件性推荐。指南强调输注前应行风险/获益评估,鉴于血制品已知风险及获益数据有限,多数患者避免输注获益;出血高风险或出血并发症可能灾难性时,应考虑输注。

要点

  • 危重症血小板减少或凝血功能障碍患者,输注血小板或新鲜冰冻血浆前应由提供者行风险/获益评估(美国胸科医师学会指南)。
  • 鉴于血制品输注的已知风险及血小板或新鲜冰冻血浆获益数据有限,多数患者避免输注这些血制品将获益(美国胸科医师学会指南)。
  • 出血高风险或出血并发症可能灾难性的患者,应考虑输注血小板或新鲜冰冻血浆(美国胸科医师学会指南)。
  • 该指南所有7个问题的证据确定性均为极低,共形成7条条件性推荐(美国胸科医师学会指南)。
  • 证据基础包括16项研究:1项随机对照试验和15项观察性研究(美国胸科医师学会指南)。

适用人群与场景

  • 危重症成人血小板减少患者,伴或不伴活动性出血。
  • 危重症成人接受常见操作时预防性输注血小板和新鲜冰冻血浆的患者。

处置流程与药物剂量

  • 危重症血小板减少或凝血功能障碍患者,输注血小板或新鲜冰冻血浆前应由提供者行风险/获益评估(条件性推荐)。
  • 鉴于血制品输注的已知风险及血小板或新鲜冰冻血浆获益数据有限,多数患者避免输注这些血制品将获益(条件性推荐)。
  • 出血高风险或出血并发症可能灾难性的患者,应考虑输注血小板或新鲜冰冻血浆(条件性推荐)。

研究设计与关键结果

  • 制定机构:美国胸科医师学会;方法:专家组提出7个PICO问题,系统证据综述,采用GRADE方法评估证据确定性并形成和分级推荐,修改德尔菲技术达成共识。
  • 初检共7,172项研究,初筛后复习100篇全文,16项研究符合纳入标准,包括1项随机对照试验和15项观察性研究。
  • 所有问题的证据确定性均为极低;专家组形成7条条件性推荐。

证据类型、等级与局限

  • 证据类型:美国胸科医师学会临床实践指南;证据确定性:所有问题均为极低;推荐强度:7条均为条件性推荐。

对床旁实践的改变

  • 危重症血小板减少或凝血功能障碍患者,输注血小板或新鲜冰冻血浆前应行风险/获益评估;多数患者避免输注获益,出血高风险或出血并发症可能灾难性时应考虑输注(美国胸科医师学会指南条件性推荐)。

指南或共识出处

  • 美国胸科医师学会临床实践指南:危重症成人新鲜冰冻血浆与血小板输注(Chest)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Platelets and fresh frozen plasma (FFP) are frequently administered to critically ill patients. Considering the variability in indications and thresholds guiding these transfusions, a comprehensive review of current evidence was conducted to provide guidance to critical care practitioners. This American College of Chest Physicians guideline examined the literature on platelet transfusions in critically ill patients with thrombocytopenia, with and without active bleeding, as well as data on prophylactic platelet and FFP transfusions for common procedures in the critical care setting.

METHODS: A panel of experts developed 7 Population, Intervention, Comparator, and Outcome questions addressing platelet and FFP transfusions in critically ill patients and performed a comprehensive evidence review. The panel applied the Grading of Recommendations, Assessment, Development, and Evaluations approach to assess the certainty of evidence, and to formulate and grade recommendations. A modified Delphi technique was used to reach consensus on the recommendations.

RESULTS: The initial search identified a total of 7,172 studies, and after the initial screening, 100 articles were reviewed. Sixteen studies met inclusion criteria, comprising 1 randomized controlled trial and 15 observational studies. Overall, the certainty of the evidence for all questions was very low. The panel formulated 7 conditional recommendations.

CONCLUSIONS: In critically ill patients with thrombocytopenia or coagulopathy, a risk/benefit assessment should be made by providers prior to transfusion of platelets or FFP. Given the known risks of blood product transfusion, and the limited data regarding the benefits from platelet or FFP transfusion, most patients will benefit from avoiding transfusion of these blood products. In patients at high risk of bleeding, or where the bleeding complication may be catastrophic, transfusion should be considered.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Coz Yataco A, Soghier I, Hébert PC, et al. Transfusion of Fresh Frozen Plasma and Platelets in Critically Ill Adults: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2025. PMID: 40074060. doi:10.1016/j.chest.2025.02.029

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。